Monash IVF Group（MIS）株式概要モナシュIVFグループ・リミテッドは、オーストラリアとマレーシアで生殖補助医療と女性専門画像診断サービスを提供しています。 詳細MIS ファンダメンタル分析スノーフレーク・スコア評価5/6将来の成長2/6過去の実績2/6財務の健全性3/6配当金3/6報酬当社が推定した公正価値より71.6%で取引されている 収益は年間16.78%増加すると予測されています 今年は黒字化を達成 同業他社や業界と比較して、良好な取引価格 リスク分析7.94%の配当はフリーキャッシュフローで十分にカバーされていない すべてのリスクチェックを見るMIS Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW483,974 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA483,974 investors already sharing narrativesYour Fair Value€Current Price€0.389.7% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-2m313m2016201920222025202620282031Revenue AU$312.8mEarnings AU$17.6mAdvancedSet Fair ValueView all narrativesMonash IVF Group Limited 競合他社LIMES SchlossklinikenSymbol: XTRA:LIKMarket cap: €168.3mMEDICLINSymbol: XTRA:MEDMarket cap: €202.4mM1 KlinikenSymbol: XTRA:M12Market cap: €319.1mRHÖN-KLINIKUMSymbol: XTRA:RHKMarket cap: €863.5m価格と性能株価の高値、安値、推移の概要Monash IVF Group過去の株価現在の株価AU$0.3852週高値AU$0.4852週安値AU$0.32ベータ0.391ヶ月の変化-5.88%3ヶ月変化-9.00%1年変化-10.70%3年間の変化-46.67%5年間の変化-27.55%IPOからの変化-66.58%最新ニュースお知らせ • Apr 20WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of 80.4% stake in Monash IVF Group Limited (ASX:MVF).WHSP Holdings Limited (ASX:SOL) and Genesis Capital entered into a non-binding indicative proposal to acquire remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million on November 24, 2025. A cash consideration valued at AUD 0.8 per share and will be paid by WHSP Holdings Limited and Genesis Capital. As part of consideration, an AUD 0.85 million is paid towards Performance Rights and AUD 250.61 million is paid towards common equity of Monash IVF Group Limited. The transaction is contingent upon exclusive due diligence, customary transaction documentation negotiation and execution, unanimous Monash IVF Group Limited recommendation, and final internal approval from WHSP Holdings Limited and Genesis Capital for a binding proposal and transaction documentation. The deal has been rejected by the board of Monash IVF Group Limited due to the Offer Price being at a substantial discount to comparable IVF transactions in the Australian market, the Proposal remaining conditional and requiring further due diligence and access to senior management and key employees, and uncertainty regarding the financing arrangements proposed by the Consortium. As of April 13, 2026 Monash IVF Group Limited has now received a revised, unsolicited, conditional and non-binding indicative proposal from WHSP Holdings Limited (ASX:SOL) and Genesis Capital. The indicative cash price offered to shareholders under the Proposal is AUD 0.90 per share. As part part of consideration AUD 281.93 million is paid towards common equity and AUD 1.68 million is paid towards performance rights. It should be noted that there is no certainty that the discussions with the Consortium will result in any transaction. If there are material developments in the future, Monash IVF will inform shareholders as required under its continuous disclosure obligations. The deal is conditional upon exclusive due diligence, including a 4-week period of exclusivity with no fiduciary exceptions, negotiation and execution of transaction documentation on 'customary terms', including a no material adverse change condition, unanimous recommendation of the Monash IVF Board of the Proposal and final internal approval from the relevant Consortium Members for a final binding proposal and entry into transaction documentation. Macquarie Capital Limited acted as financial advisor for Monash IVF Group Limited. Clayton Utz acted as legal advisor for Monash IVF Group Limited. WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of 80.4% stake in Monash IVF Group Limited (ASX:MVF) on April 20, 2026. Monash IVF Group Limited announced that its Board has unanimously rejected the revised non-binding proposal from Genesis Capital and Soul Patts to acquire the company for AUD 0.90 per share, stating the offer undervalues the company but remains open to a higher bid. This captures the rejection, the offer price, the reason, and the fact that the door remains open for a higher offer, which are the key takeaways for our tracking purposes.お知らせ • Feb 26Monash IVF Group Limited Announces Ordinary Fully Franked Interim Dividend for the Period Ended December 31, 2025, Payable on 10 April 2026Monash IVF Group Limited announced ordinary fully franked interim dividend of AUD 0.01200000 per share for the period ended December 31, 2025. The record date for the dividend is 5 March 2026 and the payment date is 10 April 2026. Ex date is March 4, 2026.お知らせ • Jan 27+ 1 more updateMonash IVF Group Limited Announces Resignation of Malik Jainudeen as Company Secretary, Effective End of April 2026Monash IVF Group Limited announced the resignation of Company Secretary, Mr. Malik Jainudeen. Mr. Jainudeen will remain with Monash IVF Group until the end of April 2026 before he commences his new role at another organisation. Malik Jainudeen has made significant contributions since joining Monash IVF Group in 2014, including stepping into the Acting CEO role during the last six months.お知らせ • Jan 23Monash IVF Group Limited to Report Fiscal Year 2026 Results on Aug 24, 2026Monash IVF Group Limited announced that they will report fiscal year 2026 results on Aug 24, 2026お知らせ • Jan 20Monash IVF Group Limited to Report First Half, 2026 Results on Feb 26, 2026Monash IVF Group Limited announced that they will report first half, 2026 results on Feb 26, 2026お知らせ • Nov 24WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million.WHSP Holdings Limited (ASX:SOL) and Genesis Capital entered into a non-binding indicative proposal to acquire remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million on November 24, 2025. A cash consideration valued at AUD 0.8 per share and will be paid by WHSP Holdings Limited and Genesis Capital. As part of consideration, an AUD 0.8 million is paid towards Performance Rights and AUD 250.61 million is paid towards common equity of Monash IVF Group Limited. The transaction is contingent upon exclusive due diligence, customary transaction documentation negotiation and execution, unanimous Monash IVF Group Limited recommendation, and final internal approval from WHSP Holdings Limited and Genesis Capital for a binding proposal and transaction documentation. The deal has been rejected by the board of Monash IVF Group Limited due to the Offer Price being at a substantial discount to comparable IVF transactions in the Australian market, the Proposal remaining conditional and requiring further due diligence and access to senior management and key employees, and uncertainty regarding the financing arrangements proposed by the Consortium. Macquarie Capital Limited acted as financial advisor for Monash IVF Group Limited. Clayton Utz acted as legal advisor for Monash IVF Group Limited. WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) on November 24, 2025.最新情報をもっと見るRecent updatesお知らせ • Apr 20WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of 80.4% stake in Monash IVF Group Limited (ASX:MVF).WHSP Holdings Limited (ASX:SOL) and Genesis Capital entered into a non-binding indicative proposal to acquire remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million on November 24, 2025. A cash consideration valued at AUD 0.8 per share and will be paid by WHSP Holdings Limited and Genesis Capital. As part of consideration, an AUD 0.85 million is paid towards Performance Rights and AUD 250.61 million is paid towards common equity of Monash IVF Group Limited. The transaction is contingent upon exclusive due diligence, customary transaction documentation negotiation and execution, unanimous Monash IVF Group Limited recommendation, and final internal approval from WHSP Holdings Limited and Genesis Capital for a binding proposal and transaction documentation. The deal has been rejected by the board of Monash IVF Group Limited due to the Offer Price being at a substantial discount to comparable IVF transactions in the Australian market, the Proposal remaining conditional and requiring further due diligence and access to senior management and key employees, and uncertainty regarding the financing arrangements proposed by the Consortium. As of April 13, 2026 Monash IVF Group Limited has now received a revised, unsolicited, conditional and non-binding indicative proposal from WHSP Holdings Limited (ASX:SOL) and Genesis Capital. The indicative cash price offered to shareholders under the Proposal is AUD 0.90 per share. As part part of consideration AUD 281.93 million is paid towards common equity and AUD 1.68 million is paid towards performance rights. It should be noted that there is no certainty that the discussions with the Consortium will result in any transaction. If there are material developments in the future, Monash IVF will inform shareholders as required under its continuous disclosure obligations. The deal is conditional upon exclusive due diligence, including a 4-week period of exclusivity with no fiduciary exceptions, negotiation and execution of transaction documentation on 'customary terms', including a no material adverse change condition, unanimous recommendation of the Monash IVF Board of the Proposal and final internal approval from the relevant Consortium Members for a final binding proposal and entry into transaction documentation. Macquarie Capital Limited acted as financial advisor for Monash IVF Group Limited. Clayton Utz acted as legal advisor for Monash IVF Group Limited. WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of 80.4% stake in Monash IVF Group Limited (ASX:MVF) on April 20, 2026. Monash IVF Group Limited announced that its Board has unanimously rejected the revised non-binding proposal from Genesis Capital and Soul Patts to acquire the company for AUD 0.90 per share, stating the offer undervalues the company but remains open to a higher bid. This captures the rejection, the offer price, the reason, and the fact that the door remains open for a higher offer, which are the key takeaways for our tracking purposes.お知らせ • Feb 26Monash IVF Group Limited Announces Ordinary Fully Franked Interim Dividend for the Period Ended December 31, 2025, Payable on 10 April 2026Monash IVF Group Limited announced ordinary fully franked interim dividend of AUD 0.01200000 per share for the period ended December 31, 2025. The record date for the dividend is 5 March 2026 and the payment date is 10 April 2026. Ex date is March 4, 2026.お知らせ • Jan 27+ 1 more updateMonash IVF Group Limited Announces Resignation of Malik Jainudeen as Company Secretary, Effective End of April 2026Monash IVF Group Limited announced the resignation of Company Secretary, Mr. Malik Jainudeen. Mr. Jainudeen will remain with Monash IVF Group until the end of April 2026 before he commences his new role at another organisation. Malik Jainudeen has made significant contributions since joining Monash IVF Group in 2014, including stepping into the Acting CEO role during the last six months.お知らせ • Jan 23Monash IVF Group Limited to Report Fiscal Year 2026 Results on Aug 24, 2026Monash IVF Group Limited announced that they will report fiscal year 2026 results on Aug 24, 2026お知らせ • Jan 20Monash IVF Group Limited to Report First Half, 2026 Results on Feb 26, 2026Monash IVF Group Limited announced that they will report first half, 2026 results on Feb 26, 2026お知らせ • Nov 24WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million.WHSP Holdings Limited (ASX:SOL) and Genesis Capital entered into a non-binding indicative proposal to acquire remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million on November 24, 2025. A cash consideration valued at AUD 0.8 per share and will be paid by WHSP Holdings Limited and Genesis Capital. As part of consideration, an AUD 0.8 million is paid towards Performance Rights and AUD 250.61 million is paid towards common equity of Monash IVF Group Limited. The transaction is contingent upon exclusive due diligence, customary transaction documentation negotiation and execution, unanimous Monash IVF Group Limited recommendation, and final internal approval from WHSP Holdings Limited and Genesis Capital for a binding proposal and transaction documentation. The deal has been rejected by the board of Monash IVF Group Limited due to the Offer Price being at a substantial discount to comparable IVF transactions in the Australian market, the Proposal remaining conditional and requiring further due diligence and access to senior management and key employees, and uncertainty regarding the financing arrangements proposed by the Consortium. Macquarie Capital Limited acted as financial advisor for Monash IVF Group Limited. Clayton Utz acted as legal advisor for Monash IVF Group Limited. WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) on November 24, 2025.お知らせ • Oct 20Monash IVF Group Limited, Annual General Meeting, Nov 20, 2025Monash IVF Group Limited, Annual General Meeting, Nov 20, 2025. Location: kpmg tower two, level 36, meeting room 36.17, collins square, 727 collins street, melbourne vic 3008 Australiaお知らせ • Jun 12+ 1 more updateMonash IVF Group Limited Announces CEO ChangesMonash IVF Group Limited's Board has on June 12, 2025 accepted Michael Knaap's resignation as Chief Executive Officer of the company. Since his appointment in 2019, Michael has led the organisation through a period of significant growth and transformation, and The company thanks him for his years of dedicated service. Monash IVF Group Chief Financial Officer and Company Secretary, Malik Jainudeen has been appointed as Acting Chief Executive Officer. Malik Jainudeen brings over a decade of service to Monash IVF Group, having joined in 2014 and serving as Chief Financial Officer and Company Secretary since 2019. His deep understanding of the organisation's operations, positions him as a steady and capable leader during this transitional period. With a background that includes ten years at KPMG managing audits for major ASX-listed companies, Malik combines financial understanding with a comprehensive knowledge of the healthcare sector.お知らせ • Mar 01Monash IVF Group Limited Declares Fully Franked Interim Dividend for the First Half ended 31 December 2024, Payable on 11 April 2025Monash IVF Group Limited declared fully franked interim dividend for the first half ended 31 December 2024 of 2.6 cents per share. The record date for the dividend is 7 March 2025 and the payment date is 11 April 2025.お知らせ • Jan 13+ 1 more updateMonash IVF Group Limited to Report Fiscal Year 2025 Results on Aug 22, 2025Monash IVF Group Limited announced that they will report fiscal year 2025 results on Aug 22, 2025Board Change • Dec 30Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 2 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Cathy Aston was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.New Risk • Oct 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite being loss-making. Share price has been volatile over the past 3 months (7.1% average weekly change).お知らせ • Sep 25Monash IVF Group Limited Announces Board ChangesMonash IVF Group Limited advised that Mr. Josef Czyzewski has tendered his resignation as a non-executive director. Mr. Czyzewski was appointed as a non-executive director of the Company on 4 June 2014 and has been a valuable member of the Board, Chair of the Audit & Risk Management Committee and a member of the Remuneration and Nomination Committee since commencement. Mr. Czyzewski will cease being a non-executive director of the Company on 31 October 2024. Ms Catherine Aston, who was appointed as a non-executive director of Monash IVF Group on 26 February 2024, will be appointed as Chair to the Audit & Risk Management Committee and will be a member of the Remuneration and Nomination Committee, effective from 31 October 2024.Recent Insider Transactions • Sep 18Independent Non-Executive Director recently bought €57k worth of stockOn the 16th of September, Catherine Aston bought around 77k shares on-market at roughly €0.73 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.お知らせ • Aug 24+ 1 more updateMonash IVF Group Limited Announces Ordinary Fully Franked Dividend for the Six Months Ended June 30, 2024, Payable on October 11, 2024Monash IVF Group Limited announced Ordinary fully franked dividend of AUD 0.02500000 per share for the six months ended June 30, 2024. Record Date is September 6, 2024. Ex Date is September 5, 2024. Payment Date is October 11, 2024.Reported Earnings • Aug 23Full year 2024 earnings released: AU$0.017 loss per share (vs AU$0.056 profit in FY 2023)Full year 2024 results: AU$0.017 loss per share (down from AU$0.056 profit in FY 2023). Revenue: AU$255.2m (up 20% from FY 2023). Net loss: AU$6.53m (down 130% from profit in FY 2023). Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.お知らせ • Mar 05Monash IVF Group Limited (ASX:MVF)completed the acquisition of 80% stake in Fertility North Holdings Pty Ltd.Monash IVF Group Limited (ASX:MVF) entered into Share Sale Agreement to acquire 80% stake in Fertility North Holdings Pty Ltd on December 19, 2023. The consideration for initial up-front cash consideration is estimated at AUD 12 million. Additional earn-out payments over a one to three year period may be payable, based on the achievement of certain financial targets. The AUD 0.5 million acquisition costs incurred by Monash for the half year ended December 31, 2023 includes the Fertility North acquisition. Fertility North generates approximately AUD 9 million revenue per annum. The acquisition is subject to certain conditions precedent, including Australian Competition and Consumer Commission (ACCC) approval. As of February 22, 2024, Australian Competition and Consumer Commission approved the transaction. The completion of the deal is anticipated to occur in Q3 FY24. Monash IVF Group Limited (ASX:MVF) completed the acquisition of 80% stake in Fertility North Holdings Pty Ltd on March 4, 2024.Upcoming Dividend • Feb 29Upcoming dividend of AU$0.025 per shareEligible shareholders must have bought the stock before 07 March 2024. Payment date: 05 April 2024. Payout ratio is a comfortable 73% and the cash payout ratio is 76%. Trailing yield: 3.1%. Lower than top quartile of German dividend payers (5.2%). In line with average of industry peers (3.3%).お知らせ • Feb 28Monash IVF Group Limited Appoints Cathy Aston as an Independent Non-Executive Director and A Member of the Audit and Risk Management Committee Effective from 26 February 2024Monash IVF Group Limited announced the appointment of Ms. Cathy Aston as an Independent Non-Executive Director and a member of the Audit and Risk Management Committee effective from 26 February 2024. Cathy is an experienced ASX listed non-executive director and has over 20 years' experience in executive roles across finance, marketing, strategy and technology, both in Australia and Asia. Cathy is very familiar with the IVF industry, serving on the Board of Virtus Health until its takeover in 2022. Cathy's executive roles were in the telecommunications industry, predominantly at Telstra where she worked for over 20 years. During her time at Telstra her senior roles were varied, initially focussing on finance, and over time transitioning to strategic roles across marketing, customer experience and technology. A key focus for Cathy was enabling businesses to improve their service offerings and customer experience through the use of technology. Cathy has significant experience in international expansion, in particularly in Asia, having worked in Hong Kong, Sri Lanka and India. Over the past decade Cathy has been very active in non-executive and advisory roles. Cathy is a non- executive director of ASX listed Integrated Research (Chair of the Audit and Risk Committee), IVE Group (Chair of the Risk and Compliance Committee), Macquarie Investment Management (Chair of the Audit, Risk and Compliance Committee) and IMB Bank (Chair). Previously she was on the Board of Virtus Health. Cathy's advisory roles have included work with the NSW State Government, and an Advisory Board Member of Avanseus, a Singapore based AI business. Cathy has a Bachelor of Economics (Macquarie University) and a Master of Commerce, Accounting & Law (University of NSW). She is a Graduate of the Australian Institute of Company Directors and a Senior Fellow of the Financial Services Institute of Australasia (FINSIA).Reported Earnings • Feb 27First half 2024 earnings released: EPS: AU$0.033 (vs AU$0.027 in 1H 2023)First half 2024 results: EPS: AU$0.033 (up from AU$0.027 in 1H 2023). Revenue: AU$125.7m (up 22% from 1H 2023). Net income: AU$12.8m (up 20% from 1H 2023). Profit margin: 10% (in line with 1H 2023). Revenue is forecast to grow 7.8% p.a. on average during the next 3 years, while revenues in the Healthcare industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 23% per year, which means it is well ahead of earnings.Declared Dividend • Feb 26First half dividend of AU$0.025 announcedShareholders will receive a dividend of AU$0.025. Ex-date: 7th March 2024 Payment date: 5th April 2024 Dividend yield will be 4.5%, which is higher than the industry average of 3.3%. Sustainability & Growth Dividend is covered by both earnings (73% earnings payout ratio) and cash flows (80% cash payout ratio). The dividend has decreased over the past 96 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 51% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • Jan 08+ 1 more updateMonash IVF Group Limited to Report First Half, 2024 Results on Feb 23, 2024Monash IVF Group Limited announced that they will report first half, 2024 results on Feb 23, 2024Upcoming Dividend • Aug 31Upcoming dividend of AU$0.022 per share at 3.5% yieldEligible shareholders must have bought the stock before 07 September 2023. Payment date: 11 October 2023. Payout ratio is on the higher end at 79%, and the cash payout ratio is above 100%. Trailing yield: 3.5%. Lower than top quartile of German dividend payers (4.9%). Higher than average of industry peers (2.9%).お知らせ • Aug 22Monash IVF Group Limited Announces Fully Franked Final Dividend for Fiscal Year Ended June 30, 2023, Payable on 11 October 2023Monash IVF Group Limited announced that on 22 August 2023, a fully franked final FY2023 dividend of 2.2 cents per share was declared. The record date for the dividend is 8 September 2023 and the payment date for the dividend is 11 October 2023.Reported Earnings • Aug 22Full year 2023 earnings released: EPS: AU$0.056 (vs AU$0.047 in FY 2022)Full year 2023 results: EPS: AU$0.056 (up from AU$0.047 in FY 2022). Revenue: AU$213.6m (up 11% from FY 2022). Net income: AU$21.8m (up 19% from FY 2022). Profit margin: 10% (in line with FY 2022). Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings.お知らせ • Aug 21Monash IVF Group Limited Provides Update on Class Action LawsuitAs announced to the ASX on 23 December 2020, Monash IVF Group Limited became aware that it and certain of its subsidiaries have been named as defendants ("Defendants") in proceedings filed in the Supreme Court of Victoria in relation to, or in connection with, the Group's non-invasive pre-implantation genetic screening technology (Ni-PGT or cell-free PGT-A) ("Class Action"). The plaintiffs in the Class Action have filed an amended statement of claim in relation to the Class Action. The amended statement of claim, amongst other things, seeks payment for aggravated damages and exemplary damages from the Defendants in the Class Action. No amount is specified or estimated in respect of the claim. As previously announced, Monash IVF has notified its insurer. The costs of Monash IVF's defence of the Class Action are currently being funded by its insurer. The amended part of the Class Action relating to aggravated damages and exemplary damages, and the costs of defending that, is uninsured. Legal costs and damages, if any, in excess of insurance proceeds will be funded by Monash IVF. Monash IVF continues to defend these claims and will keep the market updated in regards to its continuous disclosure obligations.お知らせ • May 29Monash IVF Group Limited (ASX:MVF) completed the acquisition of PIVET Medical Centre.Monash IVF Group Limited (ASX:MVF) agreed to acquire PIVET Medical Centre for AUD 9.4 million on May 18, 2022. Monash IVF is paying additional earn out payments over a one to two year period from completion. The acquisition is expected to be funded through Monash IVF's operating cash flows and/or debt facilities available. The PIVET brings into the Monash IVF clinician network, 9 fertility specialists who have worked together for several years. Completion is expected to occur during First Quarter 2023, subject to certain conditions precedent. As of August 26, 2022, The transaction is expected to complete by end of September 2022. As of February 21, 2023, the transaction is expected to complete by end of Q3 of FY2023. Squire Patton Boggs (UK) LLP acted as a legal advisor to PIVET Medical Centre. Monash IVF Group Limited (ASX:MVF) completed the acquisition of PIVET Medical Centre on May 29, 2023.Upcoming Dividend • Mar 01Upcoming dividend of AU$0.022 per share at 4.2% yieldEligible shareholders must have bought the stock before 08 March 2023. Payment date: 06 April 2023. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 4.2%. Lower than top quartile of German dividend payers (4.7%). Higher than average of industry peers (3.3%).Reported Earnings • Feb 21First half 2023 earnings released: EPS: AU$0.027 (vs AU$0.031 in 1H 2022)First half 2023 results: EPS: AU$0.027 (down from AU$0.031 in 1H 2022). Revenue: AU$103.3m (up 2.3% from 1H 2022). Net income: AU$10.6m (down 12% from 1H 2022). Profit margin: 10% (down from 12% in 1H 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.3% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.お知らせ • Jan 18+ 2 more updatesMonash IVF Group Limited to Report First Half, 2023 Results on Feb 21, 2023Monash IVF Group Limited announced that they will report first half, 2023 results on Feb 21, 2023Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 2 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Catherine West was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Upcoming Dividend • Sep 01Upcoming dividend of AU$0.022 per shareEligible shareholders must have bought the stock before 08 September 2022. Payment date: 07 October 2022. Payout ratio and cash payout ratio are on the higher end at 93% and 83% respectively. Trailing yield: 4.3%. Lower than top quartile of German dividend payers (4.7%). Higher than average of industry peers (3.7%).Reported Earnings • Aug 27Full year 2022 earnings released: EPS: AU$0.047 (vs AU$0.065 in FY 2021)Full year 2022 results: EPS: AU$0.047 (down from AU$0.065 in FY 2021). Revenue: AU$192.3m (up 4.7% from FY 2021). Net income: AU$18.4m (down 27% from FY 2021). Profit margin: 9.6% (down from 14% in FY 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 13%, compared to a 3.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.Board Change • Jun 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Independent Non-Executive Director Catherine West was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • May 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Independent Non-Executive Director Catherine West was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Upcoming Dividend • Sep 02Upcoming dividend of AU$0.021 per shareEligible shareholders must have bought the stock before 09 September 2021. Payment date: 08 October 2021. Trailing yield: 4.2%. Within top quartile of German dividend payers (3.1%). Higher than average of industry peers (2.2%).Reported Earnings • Aug 25Full year 2021 earnings released: EPS AU$0.065 (vs AU$0.046 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$183.6m (up 26% from FY 2020). Net income: AU$25.1m (up 115% from FY 2020). Profit margin: 14% (up from 8.1% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.Recent Insider Transactions • May 01Independent Non-Executive Director recently bought €124k worth of stockOn the 26th of April, Neil Broekhuizen bought around 217k shares on-market at roughly €0.57 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €146k more in shares than they have sold in the last 12 months.Analyst Estimate Surprise Post Earnings • Feb 25Revenue beats expectationsRevenue exceeded analyst estimates by 4.3%. Over the next year, revenue is forecast to grow 6.0%, compared to a 3.4% growth forecast for the Healthcare industry in Germany.Reported Earnings • Feb 25First half 2021 earnings released: EPS AU$0.037 (vs AU$0.035 in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: AU$90.8m (up 18% from 1H 2020). Net income: AU$14.6m (up 79% from 1H 2020). Profit margin: 16% (up from 11% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.Is New 90 Day High Low • Feb 18New 90-day high: €0.51The company is up 11% from its price of €0.46 on 19 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €0.56 per share.Is New 90 Day High Low • Dec 23New 90-day high: €0.48The company is up 39% from its price of €0.34 on 24 September 2020. The German market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €0.53 per share.Is New 90 Day High Low • Nov 11New 90-day high: €0.44The company is up 38% from its price of €0.32 on 13 August 2020. The German market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €0.45 per share.株主還元MISDE HealthcareDE 市場7D-2.0%3.8%0.5%1Y-10.7%2.3%-0.9%株主還元を見る業界別リターン: MIS過去 1 年間で2.3 % の収益を上げたGerman Healthcare業界を下回りました。リターン対市場: MISは、過去 1 年間で-0.9 % のリターンを上げたGerman市場を下回りました。価格変動Is MIS's price volatile compared to industry and market?MIS volatilityMIS Average Weekly Movement3.9%Healthcare Industry Average Movement5.1%Market Average Movement5.4%10% most volatile stocks in DE Market12.5%10% least volatile stocks in DE Market2.6%安定した株価: MIS 、 German市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: MISの 週次ボラティリティ は、過去 1 年間で13%から4%に減少しました。会社概要設立従業員CEO（最高経営責任者ウェブサイト2014892Victoria Atkinsonwww.monashivfgroup.com.auモナシュIVFグループ・リミテッドは、オーストラリアとマレーシアで生殖補助医療と女性専門画像診断サービスを提供している。同社は産科診断、婦人科超音波診断、不妊治療サービスを提供している。また、三次レベルの出生前診断、体外受精治療サービスも提供している。モナシュIVFグループ・リミテッドは2014年に法人化され、オーストラリアのクレモーンに拠点を置く。もっと見るMonash IVF Group Limited 基礎のまとめMonash IVF Group の収益と売上を時価総額と比較するとどうか。MIS 基礎統計学時価総額€156.68m収益（TTM）€9.30m売上高(TTM)€165.39m16.8xPER（株価収益率0.9xP/SレシオMIS は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計MIS 損益計算書（TTM）収益AU$269.39m売上原価AU$185.18m売上総利益AU$84.22mその他の費用AU$69.06m収益AU$15.16m直近の収益報告Dec 31, 2025次回決算日Aug 24, 2026一株当たり利益（EPS）0.039グロス・マージン31.26%純利益率5.63%有利子負債／自己資本比率39.8%MIS の長期的なパフォーマンスは？過去の実績と比較を見る配当金7.9%現在の配当利回り31%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/24 00:58終値2026/07/24 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Monash IVF Group Limited 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。15 アナリスト機関Martyn JacobsBell PotterTara SperanzaBell PotterBradley WatsonBell Potter12 その他のアナリストを表示
お知らせ • Apr 20WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of 80.4% stake in Monash IVF Group Limited (ASX:MVF).WHSP Holdings Limited (ASX:SOL) and Genesis Capital entered into a non-binding indicative proposal to acquire remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million on November 24, 2025. A cash consideration valued at AUD 0.8 per share and will be paid by WHSP Holdings Limited and Genesis Capital. As part of consideration, an AUD 0.85 million is paid towards Performance Rights and AUD 250.61 million is paid towards common equity of Monash IVF Group Limited. The transaction is contingent upon exclusive due diligence, customary transaction documentation negotiation and execution, unanimous Monash IVF Group Limited recommendation, and final internal approval from WHSP Holdings Limited and Genesis Capital for a binding proposal and transaction documentation. The deal has been rejected by the board of Monash IVF Group Limited due to the Offer Price being at a substantial discount to comparable IVF transactions in the Australian market, the Proposal remaining conditional and requiring further due diligence and access to senior management and key employees, and uncertainty regarding the financing arrangements proposed by the Consortium. As of April 13, 2026 Monash IVF Group Limited has now received a revised, unsolicited, conditional and non-binding indicative proposal from WHSP Holdings Limited (ASX:SOL) and Genesis Capital. The indicative cash price offered to shareholders under the Proposal is AUD 0.90 per share. As part part of consideration AUD 281.93 million is paid towards common equity and AUD 1.68 million is paid towards performance rights. It should be noted that there is no certainty that the discussions with the Consortium will result in any transaction. If there are material developments in the future, Monash IVF will inform shareholders as required under its continuous disclosure obligations. The deal is conditional upon exclusive due diligence, including a 4-week period of exclusivity with no fiduciary exceptions, negotiation and execution of transaction documentation on 'customary terms', including a no material adverse change condition, unanimous recommendation of the Monash IVF Board of the Proposal and final internal approval from the relevant Consortium Members for a final binding proposal and entry into transaction documentation. Macquarie Capital Limited acted as financial advisor for Monash IVF Group Limited. Clayton Utz acted as legal advisor for Monash IVF Group Limited. WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of 80.4% stake in Monash IVF Group Limited (ASX:MVF) on April 20, 2026. Monash IVF Group Limited announced that its Board has unanimously rejected the revised non-binding proposal from Genesis Capital and Soul Patts to acquire the company for AUD 0.90 per share, stating the offer undervalues the company but remains open to a higher bid. This captures the rejection, the offer price, the reason, and the fact that the door remains open for a higher offer, which are the key takeaways for our tracking purposes.
お知らせ • Feb 26Monash IVF Group Limited Announces Ordinary Fully Franked Interim Dividend for the Period Ended December 31, 2025, Payable on 10 April 2026Monash IVF Group Limited announced ordinary fully franked interim dividend of AUD 0.01200000 per share for the period ended December 31, 2025. The record date for the dividend is 5 March 2026 and the payment date is 10 April 2026. Ex date is March 4, 2026.
お知らせ • Jan 27+ 1 more updateMonash IVF Group Limited Announces Resignation of Malik Jainudeen as Company Secretary, Effective End of April 2026Monash IVF Group Limited announced the resignation of Company Secretary, Mr. Malik Jainudeen. Mr. Jainudeen will remain with Monash IVF Group until the end of April 2026 before he commences his new role at another organisation. Malik Jainudeen has made significant contributions since joining Monash IVF Group in 2014, including stepping into the Acting CEO role during the last six months.
お知らせ • Jan 23Monash IVF Group Limited to Report Fiscal Year 2026 Results on Aug 24, 2026Monash IVF Group Limited announced that they will report fiscal year 2026 results on Aug 24, 2026
お知らせ • Jan 20Monash IVF Group Limited to Report First Half, 2026 Results on Feb 26, 2026Monash IVF Group Limited announced that they will report first half, 2026 results on Feb 26, 2026
お知らせ • Nov 24WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million.WHSP Holdings Limited (ASX:SOL) and Genesis Capital entered into a non-binding indicative proposal to acquire remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million on November 24, 2025. A cash consideration valued at AUD 0.8 per share and will be paid by WHSP Holdings Limited and Genesis Capital. As part of consideration, an AUD 0.8 million is paid towards Performance Rights and AUD 250.61 million is paid towards common equity of Monash IVF Group Limited. The transaction is contingent upon exclusive due diligence, customary transaction documentation negotiation and execution, unanimous Monash IVF Group Limited recommendation, and final internal approval from WHSP Holdings Limited and Genesis Capital for a binding proposal and transaction documentation. The deal has been rejected by the board of Monash IVF Group Limited due to the Offer Price being at a substantial discount to comparable IVF transactions in the Australian market, the Proposal remaining conditional and requiring further due diligence and access to senior management and key employees, and uncertainty regarding the financing arrangements proposed by the Consortium. Macquarie Capital Limited acted as financial advisor for Monash IVF Group Limited. Clayton Utz acted as legal advisor for Monash IVF Group Limited. WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) on November 24, 2025.
お知らせ • Apr 20WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of 80.4% stake in Monash IVF Group Limited (ASX:MVF).WHSP Holdings Limited (ASX:SOL) and Genesis Capital entered into a non-binding indicative proposal to acquire remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million on November 24, 2025. A cash consideration valued at AUD 0.8 per share and will be paid by WHSP Holdings Limited and Genesis Capital. As part of consideration, an AUD 0.85 million is paid towards Performance Rights and AUD 250.61 million is paid towards common equity of Monash IVF Group Limited. The transaction is contingent upon exclusive due diligence, customary transaction documentation negotiation and execution, unanimous Monash IVF Group Limited recommendation, and final internal approval from WHSP Holdings Limited and Genesis Capital for a binding proposal and transaction documentation. The deal has been rejected by the board of Monash IVF Group Limited due to the Offer Price being at a substantial discount to comparable IVF transactions in the Australian market, the Proposal remaining conditional and requiring further due diligence and access to senior management and key employees, and uncertainty regarding the financing arrangements proposed by the Consortium. As of April 13, 2026 Monash IVF Group Limited has now received a revised, unsolicited, conditional and non-binding indicative proposal from WHSP Holdings Limited (ASX:SOL) and Genesis Capital. The indicative cash price offered to shareholders under the Proposal is AUD 0.90 per share. As part part of consideration AUD 281.93 million is paid towards common equity and AUD 1.68 million is paid towards performance rights. It should be noted that there is no certainty that the discussions with the Consortium will result in any transaction. If there are material developments in the future, Monash IVF will inform shareholders as required under its continuous disclosure obligations. The deal is conditional upon exclusive due diligence, including a 4-week period of exclusivity with no fiduciary exceptions, negotiation and execution of transaction documentation on 'customary terms', including a no material adverse change condition, unanimous recommendation of the Monash IVF Board of the Proposal and final internal approval from the relevant Consortium Members for a final binding proposal and entry into transaction documentation. Macquarie Capital Limited acted as financial advisor for Monash IVF Group Limited. Clayton Utz acted as legal advisor for Monash IVF Group Limited. WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of 80.4% stake in Monash IVF Group Limited (ASX:MVF) on April 20, 2026. Monash IVF Group Limited announced that its Board has unanimously rejected the revised non-binding proposal from Genesis Capital and Soul Patts to acquire the company for AUD 0.90 per share, stating the offer undervalues the company but remains open to a higher bid. This captures the rejection, the offer price, the reason, and the fact that the door remains open for a higher offer, which are the key takeaways for our tracking purposes.
お知らせ • Feb 26Monash IVF Group Limited Announces Ordinary Fully Franked Interim Dividend for the Period Ended December 31, 2025, Payable on 10 April 2026Monash IVF Group Limited announced ordinary fully franked interim dividend of AUD 0.01200000 per share for the period ended December 31, 2025. The record date for the dividend is 5 March 2026 and the payment date is 10 April 2026. Ex date is March 4, 2026.
お知らせ • Jan 27+ 1 more updateMonash IVF Group Limited Announces Resignation of Malik Jainudeen as Company Secretary, Effective End of April 2026Monash IVF Group Limited announced the resignation of Company Secretary, Mr. Malik Jainudeen. Mr. Jainudeen will remain with Monash IVF Group until the end of April 2026 before he commences his new role at another organisation. Malik Jainudeen has made significant contributions since joining Monash IVF Group in 2014, including stepping into the Acting CEO role during the last six months.
お知らせ • Jan 23Monash IVF Group Limited to Report Fiscal Year 2026 Results on Aug 24, 2026Monash IVF Group Limited announced that they will report fiscal year 2026 results on Aug 24, 2026
お知らせ • Jan 20Monash IVF Group Limited to Report First Half, 2026 Results on Feb 26, 2026Monash IVF Group Limited announced that they will report first half, 2026 results on Feb 26, 2026
お知らせ • Nov 24WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million.WHSP Holdings Limited (ASX:SOL) and Genesis Capital entered into a non-binding indicative proposal to acquire remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million on November 24, 2025. A cash consideration valued at AUD 0.8 per share and will be paid by WHSP Holdings Limited and Genesis Capital. As part of consideration, an AUD 0.8 million is paid towards Performance Rights and AUD 250.61 million is paid towards common equity of Monash IVF Group Limited. The transaction is contingent upon exclusive due diligence, customary transaction documentation negotiation and execution, unanimous Monash IVF Group Limited recommendation, and final internal approval from WHSP Holdings Limited and Genesis Capital for a binding proposal and transaction documentation. The deal has been rejected by the board of Monash IVF Group Limited due to the Offer Price being at a substantial discount to comparable IVF transactions in the Australian market, the Proposal remaining conditional and requiring further due diligence and access to senior management and key employees, and uncertainty regarding the financing arrangements proposed by the Consortium. Macquarie Capital Limited acted as financial advisor for Monash IVF Group Limited. Clayton Utz acted as legal advisor for Monash IVF Group Limited. WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) on November 24, 2025.
お知らせ • Oct 20Monash IVF Group Limited, Annual General Meeting, Nov 20, 2025Monash IVF Group Limited, Annual General Meeting, Nov 20, 2025. Location: kpmg tower two, level 36, meeting room 36.17, collins square, 727 collins street, melbourne vic 3008 Australia
お知らせ • Jun 12+ 1 more updateMonash IVF Group Limited Announces CEO ChangesMonash IVF Group Limited's Board has on June 12, 2025 accepted Michael Knaap's resignation as Chief Executive Officer of the company. Since his appointment in 2019, Michael has led the organisation through a period of significant growth and transformation, and The company thanks him for his years of dedicated service. Monash IVF Group Chief Financial Officer and Company Secretary, Malik Jainudeen has been appointed as Acting Chief Executive Officer. Malik Jainudeen brings over a decade of service to Monash IVF Group, having joined in 2014 and serving as Chief Financial Officer and Company Secretary since 2019. His deep understanding of the organisation's operations, positions him as a steady and capable leader during this transitional period. With a background that includes ten years at KPMG managing audits for major ASX-listed companies, Malik combines financial understanding with a comprehensive knowledge of the healthcare sector.
お知らせ • Mar 01Monash IVF Group Limited Declares Fully Franked Interim Dividend for the First Half ended 31 December 2024, Payable on 11 April 2025Monash IVF Group Limited declared fully franked interim dividend for the first half ended 31 December 2024 of 2.6 cents per share. The record date for the dividend is 7 March 2025 and the payment date is 11 April 2025.
お知らせ • Jan 13+ 1 more updateMonash IVF Group Limited to Report Fiscal Year 2025 Results on Aug 22, 2025Monash IVF Group Limited announced that they will report fiscal year 2025 results on Aug 22, 2025
Board Change • Dec 30Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 2 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Cathy Aston was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
New Risk • Oct 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite being loss-making. Share price has been volatile over the past 3 months (7.1% average weekly change).
お知らせ • Sep 25Monash IVF Group Limited Announces Board ChangesMonash IVF Group Limited advised that Mr. Josef Czyzewski has tendered his resignation as a non-executive director. Mr. Czyzewski was appointed as a non-executive director of the Company on 4 June 2014 and has been a valuable member of the Board, Chair of the Audit & Risk Management Committee and a member of the Remuneration and Nomination Committee since commencement. Mr. Czyzewski will cease being a non-executive director of the Company on 31 October 2024. Ms Catherine Aston, who was appointed as a non-executive director of Monash IVF Group on 26 February 2024, will be appointed as Chair to the Audit & Risk Management Committee and will be a member of the Remuneration and Nomination Committee, effective from 31 October 2024.
Recent Insider Transactions • Sep 18Independent Non-Executive Director recently bought €57k worth of stockOn the 16th of September, Catherine Aston bought around 77k shares on-market at roughly €0.73 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
お知らせ • Aug 24+ 1 more updateMonash IVF Group Limited Announces Ordinary Fully Franked Dividend for the Six Months Ended June 30, 2024, Payable on October 11, 2024Monash IVF Group Limited announced Ordinary fully franked dividend of AUD 0.02500000 per share for the six months ended June 30, 2024. Record Date is September 6, 2024. Ex Date is September 5, 2024. Payment Date is October 11, 2024.
Reported Earnings • Aug 23Full year 2024 earnings released: AU$0.017 loss per share (vs AU$0.056 profit in FY 2023)Full year 2024 results: AU$0.017 loss per share (down from AU$0.056 profit in FY 2023). Revenue: AU$255.2m (up 20% from FY 2023). Net loss: AU$6.53m (down 130% from profit in FY 2023). Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.
お知らせ • Mar 05Monash IVF Group Limited (ASX:MVF)completed the acquisition of 80% stake in Fertility North Holdings Pty Ltd.Monash IVF Group Limited (ASX:MVF) entered into Share Sale Agreement to acquire 80% stake in Fertility North Holdings Pty Ltd on December 19, 2023. The consideration for initial up-front cash consideration is estimated at AUD 12 million. Additional earn-out payments over a one to three year period may be payable, based on the achievement of certain financial targets. The AUD 0.5 million acquisition costs incurred by Monash for the half year ended December 31, 2023 includes the Fertility North acquisition. Fertility North generates approximately AUD 9 million revenue per annum. The acquisition is subject to certain conditions precedent, including Australian Competition and Consumer Commission (ACCC) approval. As of February 22, 2024, Australian Competition and Consumer Commission approved the transaction. The completion of the deal is anticipated to occur in Q3 FY24. Monash IVF Group Limited (ASX:MVF) completed the acquisition of 80% stake in Fertility North Holdings Pty Ltd on March 4, 2024.
Upcoming Dividend • Feb 29Upcoming dividend of AU$0.025 per shareEligible shareholders must have bought the stock before 07 March 2024. Payment date: 05 April 2024. Payout ratio is a comfortable 73% and the cash payout ratio is 76%. Trailing yield: 3.1%. Lower than top quartile of German dividend payers (5.2%). In line with average of industry peers (3.3%).
お知らせ • Feb 28Monash IVF Group Limited Appoints Cathy Aston as an Independent Non-Executive Director and A Member of the Audit and Risk Management Committee Effective from 26 February 2024Monash IVF Group Limited announced the appointment of Ms. Cathy Aston as an Independent Non-Executive Director and a member of the Audit and Risk Management Committee effective from 26 February 2024. Cathy is an experienced ASX listed non-executive director and has over 20 years' experience in executive roles across finance, marketing, strategy and technology, both in Australia and Asia. Cathy is very familiar with the IVF industry, serving on the Board of Virtus Health until its takeover in 2022. Cathy's executive roles were in the telecommunications industry, predominantly at Telstra where she worked for over 20 years. During her time at Telstra her senior roles were varied, initially focussing on finance, and over time transitioning to strategic roles across marketing, customer experience and technology. A key focus for Cathy was enabling businesses to improve their service offerings and customer experience through the use of technology. Cathy has significant experience in international expansion, in particularly in Asia, having worked in Hong Kong, Sri Lanka and India. Over the past decade Cathy has been very active in non-executive and advisory roles. Cathy is a non- executive director of ASX listed Integrated Research (Chair of the Audit and Risk Committee), IVE Group (Chair of the Risk and Compliance Committee), Macquarie Investment Management (Chair of the Audit, Risk and Compliance Committee) and IMB Bank (Chair). Previously she was on the Board of Virtus Health. Cathy's advisory roles have included work with the NSW State Government, and an Advisory Board Member of Avanseus, a Singapore based AI business. Cathy has a Bachelor of Economics (Macquarie University) and a Master of Commerce, Accounting & Law (University of NSW). She is a Graduate of the Australian Institute of Company Directors and a Senior Fellow of the Financial Services Institute of Australasia (FINSIA).
Reported Earnings • Feb 27First half 2024 earnings released: EPS: AU$0.033 (vs AU$0.027 in 1H 2023)First half 2024 results: EPS: AU$0.033 (up from AU$0.027 in 1H 2023). Revenue: AU$125.7m (up 22% from 1H 2023). Net income: AU$12.8m (up 20% from 1H 2023). Profit margin: 10% (in line with 1H 2023). Revenue is forecast to grow 7.8% p.a. on average during the next 3 years, while revenues in the Healthcare industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 23% per year, which means it is well ahead of earnings.
Declared Dividend • Feb 26First half dividend of AU$0.025 announcedShareholders will receive a dividend of AU$0.025. Ex-date: 7th March 2024 Payment date: 5th April 2024 Dividend yield will be 4.5%, which is higher than the industry average of 3.3%. Sustainability & Growth Dividend is covered by both earnings (73% earnings payout ratio) and cash flows (80% cash payout ratio). The dividend has decreased over the past 96 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 51% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • Jan 08+ 1 more updateMonash IVF Group Limited to Report First Half, 2024 Results on Feb 23, 2024Monash IVF Group Limited announced that they will report first half, 2024 results on Feb 23, 2024
Upcoming Dividend • Aug 31Upcoming dividend of AU$0.022 per share at 3.5% yieldEligible shareholders must have bought the stock before 07 September 2023. Payment date: 11 October 2023. Payout ratio is on the higher end at 79%, and the cash payout ratio is above 100%. Trailing yield: 3.5%. Lower than top quartile of German dividend payers (4.9%). Higher than average of industry peers (2.9%).
お知らせ • Aug 22Monash IVF Group Limited Announces Fully Franked Final Dividend for Fiscal Year Ended June 30, 2023, Payable on 11 October 2023Monash IVF Group Limited announced that on 22 August 2023, a fully franked final FY2023 dividend of 2.2 cents per share was declared. The record date for the dividend is 8 September 2023 and the payment date for the dividend is 11 October 2023.
Reported Earnings • Aug 22Full year 2023 earnings released: EPS: AU$0.056 (vs AU$0.047 in FY 2022)Full year 2023 results: EPS: AU$0.056 (up from AU$0.047 in FY 2022). Revenue: AU$213.6m (up 11% from FY 2022). Net income: AU$21.8m (up 19% from FY 2022). Profit margin: 10% (in line with FY 2022). Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings.
お知らせ • Aug 21Monash IVF Group Limited Provides Update on Class Action LawsuitAs announced to the ASX on 23 December 2020, Monash IVF Group Limited became aware that it and certain of its subsidiaries have been named as defendants ("Defendants") in proceedings filed in the Supreme Court of Victoria in relation to, or in connection with, the Group's non-invasive pre-implantation genetic screening technology (Ni-PGT or cell-free PGT-A) ("Class Action"). The plaintiffs in the Class Action have filed an amended statement of claim in relation to the Class Action. The amended statement of claim, amongst other things, seeks payment for aggravated damages and exemplary damages from the Defendants in the Class Action. No amount is specified or estimated in respect of the claim. As previously announced, Monash IVF has notified its insurer. The costs of Monash IVF's defence of the Class Action are currently being funded by its insurer. The amended part of the Class Action relating to aggravated damages and exemplary damages, and the costs of defending that, is uninsured. Legal costs and damages, if any, in excess of insurance proceeds will be funded by Monash IVF. Monash IVF continues to defend these claims and will keep the market updated in regards to its continuous disclosure obligations.
お知らせ • May 29Monash IVF Group Limited (ASX:MVF) completed the acquisition of PIVET Medical Centre.Monash IVF Group Limited (ASX:MVF) agreed to acquire PIVET Medical Centre for AUD 9.4 million on May 18, 2022. Monash IVF is paying additional earn out payments over a one to two year period from completion. The acquisition is expected to be funded through Monash IVF's operating cash flows and/or debt facilities available. The PIVET brings into the Monash IVF clinician network, 9 fertility specialists who have worked together for several years. Completion is expected to occur during First Quarter 2023, subject to certain conditions precedent. As of August 26, 2022, The transaction is expected to complete by end of September 2022. As of February 21, 2023, the transaction is expected to complete by end of Q3 of FY2023. Squire Patton Boggs (UK) LLP acted as a legal advisor to PIVET Medical Centre. Monash IVF Group Limited (ASX:MVF) completed the acquisition of PIVET Medical Centre on May 29, 2023.
Upcoming Dividend • Mar 01Upcoming dividend of AU$0.022 per share at 4.2% yieldEligible shareholders must have bought the stock before 08 March 2023. Payment date: 06 April 2023. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 4.2%. Lower than top quartile of German dividend payers (4.7%). Higher than average of industry peers (3.3%).
Reported Earnings • Feb 21First half 2023 earnings released: EPS: AU$0.027 (vs AU$0.031 in 1H 2022)First half 2023 results: EPS: AU$0.027 (down from AU$0.031 in 1H 2022). Revenue: AU$103.3m (up 2.3% from 1H 2022). Net income: AU$10.6m (down 12% from 1H 2022). Profit margin: 10% (down from 12% in 1H 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.3% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.
お知らせ • Jan 18+ 2 more updatesMonash IVF Group Limited to Report First Half, 2023 Results on Feb 21, 2023Monash IVF Group Limited announced that they will report first half, 2023 results on Feb 21, 2023
Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 2 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Catherine West was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Upcoming Dividend • Sep 01Upcoming dividend of AU$0.022 per shareEligible shareholders must have bought the stock before 08 September 2022. Payment date: 07 October 2022. Payout ratio and cash payout ratio are on the higher end at 93% and 83% respectively. Trailing yield: 4.3%. Lower than top quartile of German dividend payers (4.7%). Higher than average of industry peers (3.7%).
Reported Earnings • Aug 27Full year 2022 earnings released: EPS: AU$0.047 (vs AU$0.065 in FY 2021)Full year 2022 results: EPS: AU$0.047 (down from AU$0.065 in FY 2021). Revenue: AU$192.3m (up 4.7% from FY 2021). Net income: AU$18.4m (down 27% from FY 2021). Profit margin: 9.6% (down from 14% in FY 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 13%, compared to a 3.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.
Board Change • Jun 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Independent Non-Executive Director Catherine West was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • May 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Independent Non-Executive Director Catherine West was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Upcoming Dividend • Sep 02Upcoming dividend of AU$0.021 per shareEligible shareholders must have bought the stock before 09 September 2021. Payment date: 08 October 2021. Trailing yield: 4.2%. Within top quartile of German dividend payers (3.1%). Higher than average of industry peers (2.2%).
Reported Earnings • Aug 25Full year 2021 earnings released: EPS AU$0.065 (vs AU$0.046 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$183.6m (up 26% from FY 2020). Net income: AU$25.1m (up 115% from FY 2020). Profit margin: 14% (up from 8.1% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.
Recent Insider Transactions • May 01Independent Non-Executive Director recently bought €124k worth of stockOn the 26th of April, Neil Broekhuizen bought around 217k shares on-market at roughly €0.57 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €146k more in shares than they have sold in the last 12 months.
Analyst Estimate Surprise Post Earnings • Feb 25Revenue beats expectationsRevenue exceeded analyst estimates by 4.3%. Over the next year, revenue is forecast to grow 6.0%, compared to a 3.4% growth forecast for the Healthcare industry in Germany.
Reported Earnings • Feb 25First half 2021 earnings released: EPS AU$0.037 (vs AU$0.035 in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: AU$90.8m (up 18% from 1H 2020). Net income: AU$14.6m (up 79% from 1H 2020). Profit margin: 16% (up from 11% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.
Is New 90 Day High Low • Feb 18New 90-day high: €0.51The company is up 11% from its price of €0.46 on 19 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €0.56 per share.
Is New 90 Day High Low • Dec 23New 90-day high: €0.48The company is up 39% from its price of €0.34 on 24 September 2020. The German market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €0.53 per share.
Is New 90 Day High Low • Nov 11New 90-day high: €0.44The company is up 38% from its price of €0.32 on 13 August 2020. The German market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €0.45 per share.
